US 8501682
Difluorinated tripeptides as HCV serine protease inhibitors
granted A61PA61P31/00A61P31/12
Quick answer
US patent 8501682 (Difluorinated tripeptides as HCV serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61P, A61P31/00, A61P31/12, A61P31/14, A61P43/00